Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Attitudes toward attention-deficit hyperactivity disorder (ADHD) treatment: parents' and children's perspectives.

Berger I, Dor T, Nevo Y, Goldzweig G.

J Child Neurol. 2008 Sep;23(9):1036-42. doi: 10.1177/0883073808317726.

PMID:
18487521
2.
3.

Child and parent perceptions of stimulant medication treatment in attention deficit hyperactivity disorder.

Efron D, Jarman FC, Barker MJ.

J Paediatr Child Health. 1998 Jun;34(3):288-92.

PMID:
9633980
4.

Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.

Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.

Psychiatry Clin Neurosci. 2009 Apr;63(2):167-75. doi: 10.1111/j.1440-1819.2009.01937.x.

5.

Mothers' and children's perceptions of medication for children with attention-deficit hyperactivity disorder.

McNeal RE, Roberts MC, Barone VJ.

Child Psychiatry Hum Dev. 2000 Spring;30(3):173-87.

PMID:
10851792
6.
7.

Treatment choices and experiences in attention deficit and hyperactivity disorder: relations to parents' beliefs and attributions.

Johnston C, Seipp C, Hommersen P, Hoza B, Fine S.

Child Care Health Dev. 2005 Nov;31(6):669-77.

PMID:
16207224
8.

Comments on efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.

Pae CU.

Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jun 30;31(5):1149-50; author reply 1151-2. No abstract available.

PMID:
17493730
9.

Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials.

Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R.

Clin Ther. 2009 Aug;31(8):1844-55. doi: 10.1016/j.clinthera.2009.08.002.

PMID:
19808143
10.

Efficacy of osmotic-release oral system (OROS) methylphenidate for mothers with attention-deficit/hyperactivity disorder (ADHD): preliminary report of effects on ADHD symptoms and parenting.

Chronis-Tuscano A, Seymour KE, Stein MA, Jones HA, Jiles CD, Rooney ME, Conlon CJ, Efron LA, Wagner SA, Pian J, Robb AS.

J Clin Psychiatry. 2008 Dec;69(12):1938-47.

PMID:
19192455
11.

Stimulant medication and attention deficit-hyperactivity disorder. The child's perspective.

Bowen J, Fenton T, Rappaport L.

Am J Dis Child. 1991 Mar;145(3):291-5.

PMID:
2003477
12.

Parental angst making and revisiting decisions about treatment of attention-deficit/hyperactivity disorder.

Brinkman WB, Sherman SN, Zmitrovich AR, Visscher MO, Crosby LE, Phelan KJ, Donovan EF.

Pediatrics. 2009 Aug;124(2):580-9. doi: 10.1542/peds.2008-2569.

PMID:
19651580
13.
15.

Parental perceptions and satisfaction with stimulant medication for attention-deficit hyperactivity disorder.

Dosreis S, Zito JM, Safer DJ, Soeken KL, Mitchell JW Jr, Ellwood LC.

J Dev Behav Pediatr. 2003 Jun;24(3):155-62.

PMID:
12806227
16.

Children's and parents' perspectives on open-label use of placebos in the treatment of ADHD.

Sandler A, Glesne C, Geller G.

Child Care Health Dev. 2008 Jan;34(1):111-20. doi: 10.1111/j.1365-2214.2007.00743.x.

PMID:
18171452
17.

No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.

Walitza S, Kämpf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H.

Toxicol Lett. 2009 Jan 10;184(1):38-43. doi: 10.1016/j.toxlet.2008.10.011.

PMID:
19015014
18.

Attention-deficit-hyperactivity disorder: an update.

Dopheide JA, Pliszka SR.

Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Review.

PMID:
19476419
19.

Children's self-reports on perceived effects on taking stimulant medication for ADHD.

Thorell LB, Dahlström K.

J Atten Disord. 2009 Mar;12(5):460-8. doi: 10.1177/1087054708320430.

PMID:
18685139
20.

Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate : a chart review of Spanish adults with attention-deficit hyperactivity disorder.

Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gómez N, Yelmo S, Ferrer M, Martínez Y, Casas M.

CNS Drugs. 2008;22(7):603-11.

PMID:
18547128

Supplemental Content

Support Center